Skip to main content
Premium Trial:

Request an Annual Quote

Emergent, Sanofi Pasteur to Co-Develop Meningitis B Vaccine

NEW YORK, June 5 (GenomeWeb News) - Sanofi Pasteur has obtained exclusive rights to Emergent's proteins and related technology to be used for the development of a vaccine to protect against Neisseria meningitidis serogroup B, or meningitis B bacterial infections.

 

Sanofi Pasteur, which is the vaccine business of the Sanofi-Aventis group, paid Emergent 3 million ($3.9 million) as an up-front license fee. It will also pay Emergent for all development services provided in advancing a vaccine through Phase I clinical trials, including retrospective payment for work performed from Jan. 1 until the date of the agreement, and it will pay developmental milestones and royalties on eventual product sales.

 

Sanofi and Emergent will jointly evaluate and develop a pool of Emergent's antigens as the basis of a multivalent subunit vaccine against Neisseria meningitides infection. Emergent identified the protein candidates using its Signature-Tagged Mutagenesis functional genomics technology, in combination with functional proteomics techniques.

 

Under terms of the agreement, Emergent will have primary responsibility for development activities through Phase I clinical trials. Sanofi will have primary responsibility for development activities from initiation of Phase II studies through regulatory approval. It will also be responsible for all commercialization activities including worldwide sales and marketing.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.